Edition:
United States

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

1.46USD
18 Jan 2019
Change (% chg)

$-0.07 (-4.58%)
Prev Close
$1.53
Open
$1.53
Day's High
$1.54
Day's Low
$1.46
Volume
45,622
Avg. Vol
229,261
52-wk High
$11.08
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Sellas Life Sciences Group Inc Says Gene Mack Submitted His Resignation As CFO And Treasurer Of Co Effective Immediately
Tuesday, 18 Dec 2018 05:32pm EST 

Dec 18 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC - ON DEC 17, GENE MACK SUBMITTED HIS RESIGNATION AS CFO AND TREASURER OF CO EFFECTIVE IMMEDIATELY - SEC FILING.SELLAS LIFE SCIENCES GROUP INC - APPOINTED JOHN T. BURNS, CO’S VP, FINANCE AND CORPORATE CONTROLLER, AS CO’S INTERIM PRINCIPAL ACCOUNTING OFFICER.SELLAS LIFE SCIENCES GROUP - ENGAGED ALEKSEY KRYLOV AS CONSULTANT TO PROVIDE FINANCIAL SERVICES TO CO ON INTERIM BASIS FOR INITIAL TERM OF 3 MONTHS.  Full Article

Sellas Life Sciences Group-On Dec. 5, Board Approved Termination Of License Agreement For GALE-401 Between Mills Pharmaceuticals & Biovascular
Wednesday, 12 Dec 2018 08:31am EST 

Dec 12 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP - ON DEC. 5, BOARD APPROVED TERMINATION OF LICENSE AGREEMENT FOR GALE-401 BETWEEN MILLS PHARMACEUTICALS & BIOVASCULAR.SELLAS LIFE SCIENCES - PRELIM ESTIMATE OF PRE-TAX CHARGE IN QUARTER ENDED DEC 31, 2018 IN CONNECTION WITH TERMINATION OF BVI AGREEMENT IS ABOUT $9.7 MILLION.  Full Article

Sellas Life Sciences Announces Expedited Development Path For Galinpepimut-S Following Feedback From FDA
Wednesday, 28 Nov 2018 08:30am EST 

Nov 28 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES EXPEDITED DEVELOPMENT PATH FOR GALINPEPIMUT-S (GPS) IN ACUTE MYELOID LEUKEMIA (AML) FOLLOWING FEEDBACK FROM FDA.SELLAS LIFE SCIENCES GROUP - PLANS TO PROCEED WITH A CLINICAL STUDY DESIGN AND BIOSTATISTICAL PLAN TO SUPPORT A PHASE 3 REGISTRATIONAL STUDY.SELLAS LIFE SCIENCES GROUP INC - FAST-TRACK AND ORPHAN DRUG DESIGNATIONS FOR GPS IN AML CONTINUE TO APPLY.SELLAS LIFE SCIENCES GROUP INC - AGREEMENT ON PHASE 3 STUDY IN PATIENTS IN CR2 POISED TO REDUCE SAMPLE SIZE, TIME TO PRIMARY ENDPOINT AND COSTS.  Full Article

SELLAS Life Sciences Group Reports Qtrly Loss Per Share of $0.53
Thursday, 15 Nov 2018 07:30am EST 

Nov 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.53.SELLAS LIFE SCIENCES GROUP QTRLY LOSS PER SHARE $0.53.SELLAS LIFE SCIENCES GROUP - AS OF SEPT 30, 2018, UNRESTRICTED CASH AND CASH EQUIVALENTS TOTALED $10.0 MILLION.  Full Article

Sellas Says Independent Experts Confirmed Interim Analysis Of Mid-Stage NeuVax Trial
Friday, 19 Oct 2018 08:05am EDT 

Oct 19 (Reuters) - Sellas Life Sciences Group Inc ::DATA SAFETY MONITORING BOARD CONFIRMS TRIPLE NEGATIVE BREAST CANCER AS THE TARGET PATIENT POPULATION FOR DEVELOPMENT OF NEUVAX™ (NELIPEPIMUT-S) IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN®) IN HER2 1+/2+ BREAST CANCER PATIENTS FOLLOWING FINAL ANALYSIS OF PHASE 2B TRIAL.SELLAS LIFE SCIENCES - FINAL ANALYSIS SHOWED NO NEW SAFETY SIGNALS, SHOWED NO DIFFERENCE IN CARDIOTOXICITY BETWEEN TZ + NPS COMPARED TO TZ ALONE.SELLAS LIFE SCIENCES - DATA SAFETY MONITORING BOARD CONCLUDED FINAL DATA FROM PHASE 2B STUDY OF TRASTUZUMAB CONFIRMS PREVIOUSLY ANNOUNCED FINDINGS.SELLAS LIFE SCIENCES GROUP INC - DSMB CONCLUDED THAT THERE WAS AN INCREMENTAL IMPROVEMENT IN OUTCOMES AND STATISTICS WITH A LONGER MEDIAN FOLLOW-UP.  Full Article

Sellas Life Sciences Q2 Loss Per Share $1.26
Wednesday, 15 Aug 2018 08:00am EDT 

Aug 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.26.AS OF JUNE 30, 2018, CASH AND CASH EQUIVALENTS WERE $1.3 MILLION.  Full Article

Sellas Life Sciences Group Files For Offering Of Up To 9.4 Mln Shares
Thursday, 19 Jul 2018 05:58pm EDT 

July 19 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO 9.4 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Empery Asset Management Lp Reports 9.99 pct Passive Stake In Sellas Life Sciences Group Inc As Of July 12
Wednesday, 18 Jul 2018 01:53pm EDT 

July 18 (Reuters) - Sellas Life Sciences Group Inc ::EMPERY ASSET MANAGEMENT, LP REPORTS 9.99 PERCENT PASSIVE STAKE IN SELLAS LIFE SCIENCES GROUP INC AS OF JULY 12, 2018 - SEC FILING.  Full Article

Sellas Life Sciences Says Offering Of 6.08 Mln Shares
Tuesday, 26 Jun 2018 07:32am EDT 

June 26 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC SAYS OFFERING OF 6.08 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - ‍cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016​.  Full Article